Kawasaki disease (KD) is an acute systemic vasculitis of medium – sized vessels that affects infants and children. The etiology of KD is unclear. Typical KD requires the presence of fever of at least 5 days duration and coexisting ≥ 4/5 principal clinical features: bilateral bulbar conjunctival injection, erythema and cracking og lips, skin rash, erythema and edema of the palms and feet, unilateral cervical nonpurulent lymphadenopathy. If patient presents less than 4 of the principal clinical features, the diagnosis of incomplete KD should be considered. The basis of initiate treatment of KD is a single dose of intravenous immunoglobulin (IVIG) with acetylsalicylic acid. But about 10–20% of patients do not respond to IVIG-therapy. Timely and adequate treatment of KD by IVIG and aspirin could help to prevent the development of coronary artery lesions, thats why diagnosis of KD is very important.
REFERENCES(21)
1.
Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. Front Pediatr 2018; 6: 198.
McCrindle BW. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation 2017; 135: e927-e999.
Burns JC, Hsieh LE, Kumar J, et al. Characterization of circulating immune cells in acute Kawasaki disease suggests exposure to different antigens. Clin Exp Immunol 2020; 202: 263-272.
Mamoru A, Ryuji F, Kenji H, et al. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Circulation J 2014; 78: 2521-2562.
Lee W, Cheah CS, Suhaini SA, et al. Clinical manifestations and laboratory findings of Kawasaki disease: beyond the classic diagnostic features. Medicina 2022; 58: 734.
Fukui S, Seki M, Minami T, et al. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial. Pediatr Rheumatol Online J 2021; 19: 107.
Burns JC, Song Y, Bujold M, et al. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 2013; 174: 337-344.
Han CL, Zhao SL. Intravenous immunoglobulin gamma (IVIG) versus IVIG plus infliximab in young children with Kawasaki disease. Med Sci Monit 2018; 24: 7264-7270.
Mori M, Hara T, Kikuchi M, et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep 2018; 8: 1994.
Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health 2021; 5: 852-861.
Gałeczka M, Fiszer R, Karwot B, Głowacki J, Szkutnik M. Difficult diagnosis of Kawasaki disease in a patient with giant coronary artery aneurysms. Kardiol Pol 2017; 75: 932-932.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.